ClinDescience was founded in August 2001 by Professor Dr. Konrad Burk who is responsible for scientific and medical matters. In addition to his excellent professional qualifications, Dr. Burk has 30 years of practical experience in both clinical and industry settings, with a focus on oncology and urology.

Dr. Burk has established excellent connections with organizations and institutions that are well known in the oncology field. These relationships include such names as the Cancer Research Campaign (CRC), the German Cancer Society (DKG), the European Organization for Research and Treatment of Cancer (EORTC), the National Surgical Adjuvant Breast and Bowel Project (NSABP), the MD Anderson Cancer Center, Houston, Texas and the Memorial Sloan Kettering Cancer Center, New York, NY.

During his employment with academic hospitals as well as in clinical research and development Dr. Burk has conducted numerous clinical trials in cooperation with the aforementioned institutions. The contacts and personal relationships resulting from this, enable ClinDescience to cooperate very closely with experienced experts in toxicology, pharmacology, clinical, and regulatory in Europe and the United States.

The customized strategies and concepts developed by ClinDescience will support your decision-making in complex situations of drug development. Our goal is to contribute to a substantial reduction in the development time of your compounds.

Our expertise will help you in evaluating the potential of a compound.

The first step is a thorough risk-benefit analysis of the compound under consideration. It is important to harmonize the pre-clinical investigations and the clinical development program. In addition, the approval strategy will have a significant impact on the clinical study program.

We will draft an individual development plan for your compounds based on our scientific expertise and our many years of experience in this industry. Of specific note is our experience in dealing with the regulatory authorities governing clinical and drug development. In this area of the business, we are able to clearly determine the likelihood of success and the risks associated with different options.

The core focus of ClinDescience is to join with pharmaceutical and biotech companies in drug development from the pre-clinical phase through to the approval process. This can take place in close cooperation with the advisory boards and the regulatory authorities in Europe and the USA. Such cooperation will support your current drug development programs and will result in a reduced overall development time.

We combine a deep know-how in basic research with international experience in clinical issues and drug approval. Our relationships with internationally acclaimed experts enable us to call on their expertise when there is a need to provide second opinions.